Epigenorm Antivir Combined With Acupuncture for the Treatment of Osteoarthritis Patients Who Are Overweight or Obese

Sponsor
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology (Other)
Overall Status
Unknown status
CT.gov ID
NCT03540186
Collaborator
(none)
15
1
1
4.1
3.7

Study Details

Study Description

Brief Summary

The study evaluates analgesic, antiinflammatory and metabolic effects of a supplement Epigenome-Antivir (extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C) combined with acupuncture in patients with knee osteoarthritis (OA) and metabolic syndrome.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Epigenorm Antivir
  • Procedure: Acupuncture
N/A

Detailed Description

Epigenome-Antivir components have long been used in traditional medicine and have been shown to exert anti-inflammatory properties both in vitro and in vivo. It has also been shown that acupuncture can provide a moderate analgesic effect in osteoarthritis. It is anticipated that the combination of Epigenome-Antivir and acupuncture will reduce pain, inflammatory and metabolic markers in patients with OA and metabolic syndrome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Nutritional Supplement Epigenome Antivir Combined With Acupuncture for the Treatment of Osteoarthritis Who Are Overweight or Obese
Actual Study Start Date :
Jun 29, 2018
Anticipated Primary Completion Date :
Nov 1, 2018
Anticipated Study Completion Date :
Nov 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Epigenorm Antivir and acupuncture arm

Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.

Dietary Supplement: Epigenorm Antivir
1 capsule of Epigenorm Antivir twice daily for 3 months

Procedure: Acupuncture
Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Visual Analogue Scale for Pain [Baseline, 4 weeks, 8 weeks, 12 weeks]

    The Visual Analogue Scale for Pain varies from 0 to 10 cm. Higher values represent worse outcomes.

Secondary Outcome Measures

  1. Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Pain [Baseline, 4 weeks, 8 weeks, 12 weeks]

    KOOS Pain consists of 9 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.

  2. Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Activities of daily living (ADL) [Baseline, 4 weeks, 8 weeks, 12 weeks]

    KOOS ADL consists of 17 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.

  3. Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Symptoms [Baseline, 4 weeks, 8 weeks, 12 weeks]

    KOOS Symptoms consists of 7 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.

  4. Quality of life with the The Short Form (36) Health Survey score [Baseline, 4 weeks, 8 weeks, 12 weeks]

    he Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

  5. Intermittent and Constant Osteoarthritis Pain self-report questionnaire [Baseline, 4 weeks, 8 weeks, 12 weeks]

    Pain measure: Scale range 0-100 with higher scores indicating worse pain

  6. Changes in serum levels of aggrecan [Baseline, 8 weeks]

    serum levels of aggrecan measured in ng/ml

  7. Changes in serum levels of antibodies to collagen type II [Baseline, 8 weeks]

    serum levels of antibodies to collagen type II measured AU/ml

  8. Changes in serum levels of C-reactive protein [Baseline, 8 weeks]

    serum levels of C-reactive protein (CRP), g/l

  9. Changes in histamine levels [Baseline, 8 weeks]

    serum levels of histamine in ng/ml

  10. Changes in inflammation biomarkers [Baseline, 8 weeks]

    serum levels of (CRP), interleukin (IL)-6, IL- 18, adiponectin, IL-10, and interferon (IFN) γ in pg/ml

  11. Changes in lipid biomarkers [Baseline, 8 weeks]

    serum total cholesterol, HDL, and LDL measured in mmol/L

  12. Changes in depression scores measured with Patient Health Questionnaire-9 (PHQ9P) [Baseline, 4 weeks, 8 weeks, 12 weeks]

    The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. It consists of nine questions with responses ranging from "0" (not at all) to "3" (nearly every day). The possible range is 0-27. Higher values represent worse outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • osteoarthritis of the knee fulfilling American College of Rheumatology (ACR) criteria

  • BMI of 25 or more

Exclusion Criteria:
  • use of NSAIDs one month prior to study entry (paracetamol is allowed)

  • pregnancy and lactation

  • increased sensitivity to the study drug

  • clinically significant renal function impairment

  • use of antidepressants

  • diagnosis of bipolar disorder

  • use of symptomatic slow acting drugs of OA (SYSADOA) one month prior to study entry

  • any condition which may lead to difficulties to participation in the study from the viewpoint of Investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 Laboratory of Clinical Immunopharmacology Novosibirsk Russian Federation 630047

Sponsors and Collaborators

  • Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology

Investigators

  • Principal Investigator: Ivan Shirinsky, MD, PhD, Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ivan Shirinsky, MD, PhD, Principal Investigator, Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
ClinicalTrials.gov Identifier:
NCT03540186
Other Study ID Numbers:
  • LCI002
First Posted:
May 30, 2018
Last Update Posted:
Jul 2, 2018
Last Verified:
Jun 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 2, 2018